Literature DB >> 15449026

[Therapy-induced tumor regression in adult soft tissue sarcomas-morphological findings].

C Kuhnen1, K-M Müller, H U Steinau, M Lehnhardt.   

Abstract

Morphological findings of 21 soft tissue sarcomas of adulthood following preoperative chemo- and/or radiotherapy including perfusion therapy and resection are presented. The therapy-induced changes included a spectrum ranging from total tumor regression up to still completely vital tumor (median of all cases: 30% vital tumor tissue). 7 of 21 sarcomas (33%) were evaluated as responders (grade I-III). So-called malignant fibrous histiocytoma (MFH) revealed a good tumor response to preoperatively administered therapy (regression grades I and II). Myxoid/round-cell liposarcoma exhibited regression grades of IV-V (i.e. 30% up to 95% vital tumor tissue, non-responders). Synovial sarcoma was characterized by regression grades III up to VI (i.e. up to 100% vital tumor tissue without any signs of regression, 83% non-responders). Completely vital tumor was evident in 2 synovial sarcomas despite preoperative tumor therapy. These findings hint towards differences in response of distinct sarcoma entities to preoperative chemo-/radiotherapy. A grading of therapy-induced tumor regression in adult soft tissue sarcomas may best refer to already established grading schemes (e.g. according to the grading scheme for osteosarcomas following chemotherapy of Salzer-Kuntschik). A report of sarcoma resection specimens should include the percentage of vital tumor tissue.

Entities:  

Mesh:

Year:  2004        PMID: 15449026     DOI: 10.1007/s00292-004-0720-7

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  11 in total

1.  A future for hyperthermia in cancer treatment?

Authors:  O S Nielsen; M Horsman; J Overgaard
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

2.  [Regression grading of neoadjuvant non-small-cell lung carcinoma treatment].

Authors:  K Junker; M Thomas; K Schulmann; V Klinke; U Bosse; K M Müller
Journal:  Pathologe       Date:  1997-03       Impact factor: 1.011

3.  [Therapy-induced tumor regression. Morphological findings in malignant primary and secondary liver tumors following intensive regional cytostatic treatment].

Authors:  H P Fischer
Journal:  Pathologe       Date:  1985-01       Impact factor: 1.011

4.  [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors].

Authors:  M Salzer-Kuntschik; G Brand; G Delling
Journal:  Pathologe       Date:  1983-05       Impact factor: 1.011

5.  Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations.

Authors:  J Issakov; O Merimsky; M Gutman; Y Kollender; D Lev-Chelouche; S Abu-Abid; B Lifschitz-Mercer; M Inbar; J M Klausner; I Meller
Journal:  Ann Surg Oncol       Date:  2000-03       Impact factor: 5.344

6.  Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80.

Authors:  M Salzer-Kuntschik; G Delling; G Beron; R Sigmund
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

7.  Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.

Authors:  Eva M Noorda; Bart C Vrouenraets; Omgo E Nieweg; Frits van Coevorden; Gooike W van Slooten; Bin B R Kroon
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

8.  Therapy of prostatic cancer and histopathologic follow-up.

Authors:  G Dhom; S Degro
Journal:  Prostate       Date:  1982       Impact factor: 4.104

9.  [Therapy-induced changes in osteosarcoma after neoadjuvant chemotherapy (COSS 86 Therapy Study). Correlation between morphologic findings and clinical follow-up].

Authors:  M Werner; N Fuchs; M Salzer-Kuntschik; K Winkler; G Delling
Journal:  Pathologe       Date:  1996-01       Impact factor: 1.011

10.  [Classification, histological and cytological grading and assessment of regression grading in prostatic carcinomas. A recommendation of the Pathologic-Urological Task Force on Prostatic Carcinoma].

Authors:  B Helpap; A Böcking; G Dhom; P Faul; H Kastendieck; W Leistenschneider; H A Müller
Journal:  Pathologe       Date:  1985-01       Impact factor: 1.011

View more
  2 in total

1.  Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways.

Authors:  Marcus Lehnhardt; Ludger Klein-Hitpass; Cornelius Kuhnen; Heinz Herbert Homann; Adrien Daigeler; Hans Ulrich Steinau; Sonja Roehrs; Laura Schnoor; Lars Steinstraesser; Oliver Mueller
Journal:  BMC Cancer       Date:  2005-07-07       Impact factor: 4.430

2.  Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures.

Authors:  Adrien Daigeler; Ludger Klein-Hitpass; Michael Ansgar Chromik; Oliver Müller; Jörg Hauser; Heinz-Herbert Homann; Hans-Ulrich Steinau; Marcus Lehnhardt
Journal:  BMC Cancer       Date:  2008-10-29       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.